Hey! We are Nemo.
Nemo, short for Never Miss Out, is a mobile investment platform that delivers curated, data-driven investment ideas to your fingertips. It offers commission-free trading across stocks, ETFs, crypto, and CFDs, along with AI-powered tools, real-time market alerts, and themed stock collections called Nemes.
Download the App
Scan the QR code to download the Nemo app and start investing on Nemo today
Published on 8 November 2026
Read article
Published on 8 November 2026
Read article
Published on 8 November 2026
Read article
Published on 7 November 2026
Read article
The Courtroom Ceasefire. The high-stakes mRNA vaccine patent dispute is officially over, as both sides resolved the lingering Moderna Spikevax lawsuit that once threatened crushing royalty payouts.
Capital Unlocked. Following the pivotal GSK Moderna patent settlement, both drugmakers can now divert vital resources away from expensive legal defences and back into lucrative non-Covid respiratory pipelines.
A Calmer Horizon. Lifting the immediate courtroom cloud sharply reduces Moderna stock legal risk, potentially allowing the market to value core clinical programmes without the drag of litigation overhangs.
The Commercial Reality. Ending a lawsuit won't instantly boost flagging post-pandemic jab uptake, and new patent skirmishes could still emerge as competitors rush to dominate preventative medicine.
There are few spectacles quite as dreary, or as ruinously expensive, as pharmaceutical titans squabbling over molecular blueprints. For years, GSK and Moderna have behaved like stubborn neighbours feuding over the exact boundary of a garden hedge. Only here, the hedge involved lipid nanoparticle technology, and the prize was billions in disputed sales from Moderna's Spikevax and mResvia.
Mercifully, the adults have finally entered the room. The two firms have put down their legal weapons and agreed to a settlement.
For Moderna, this removes a particularly suffocating cloud. Nothing frightens market analysts quite like the prospect of retrospective damages or perpetual royalty drains nibbling away at gross margins. That specific nightmare has now vanished into the ether, leaving Moderna's management free to focus on laboratory work rather than funding extravagant legal fees in London and Delaware.
Yet, one must ask: does an out-of-court handshake actually solve the core commercial problem?
A courtroom victory does not generate revenue.
To my mind, lifting litigation risk is undeniably welcome, but it merely returns an investor to the cold reality of the marketplace. And that market is notoriously fickle. Post-pandemic vaccine apathy is real, competition is savage, and persuading healthcare providers to purchase next-generation jabs for respiratory syncytial virus or seasonal influenza is an uphill slog.
GSK can now pour resources into its own respiratory candidates without glancing over its shoulder. Moderna, meanwhile, must prove to cynical observers that it has a sustainable commercial life beyond the pandemic boom. It is all well and good possessing clever delivery platforms, but you still have to sell the vials. For anyone assessing the wider landscape, exploring mRNA Vaccines: Could Non-COVID Markets Drive Growth? might provide a sensible perspective on where the actual commercial battle is heading.
Does this settlement offer relief? Certainly. A major operational discount has been stripped away. But do not mistake the absence of legal peril for guaranteed financial health. Clinical pipelines are brittle, regulatory hurdles remain unforgiving, and shifting consumer demand could easily derail the best-laid plans.
In short, the lawyers have had their payday and packed their bags. Now, both businesses must face the far tougher jury of the open market.
View the full Basket:mRNA Vaccines: Could Non-COVID Markets Drive Growth?
View the full Basket:mRNA Vaccines: Could Non-COVID Markets Drive Growth?
This article is marketing material and should not be construed as investment advice. No information set out in this article be considered, as advice, recommendation, offer, or a solicitation, to buy or sell any financial product, nor is it financial, investment, or trading advice. Any references to specific financial product or investment strategy are for illustrative / educational purposes only and subject to change without notice. It is the investor’s responsibility to evaluate any prospective investment, assess their own financial situation, and seek independent professional advice. Past performance is not indicative of future results. Please refer to our Risk Disclosure.
Published on 8 November 2026
Read article
Published on 8 November 2026
Read article
Published on 8 November 2026
Read article
Published on 7 November 2026
Read article
